Paper Details

  1. Home
  2. Paper Details

Antibody and plasmablast response to 13-valent pneumococcal conjugate vaccine in chronic lymphocytic leukemia patients--preliminary report.

Author: GozdzStanislaw, GrywalskaEwelina, HusIwona, Korona-GlowniakIzabela, MalmAnna, PasiarskiMarcin, RolinskiJacek, Stelmach-GoldysAgnieszka

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study aimed to compare the immune response to PCV13 in 24 previously untreated CLL patients and healthy subjects.
Paper Details　
Original Abstract of the Article :
Chronic lymphocytic leukemia (CLL) leads to significant immune system dysfunction. The predominant clinical presentation in 50% of patients involves recurrent, often severe, infections. Infections are also the most common (60-80%) cause of deaths in CLL patients. The scope of infections varies with ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4266633/

データ提供：米国国立医学図書館（NLM）

Immune Response to Pneumococcal Conjugate Vaccine in Chronic Lymphocytic Leukemia (CLL) Patients

Chronic lymphocytic leukemia (CLL) is a challenging disease, often accompanied by a weakened immune system, making patients vulnerable to infections. This study explores the immune response to the 13-valent pneumococcal conjugate vaccine (PCV13) in CLL patients. The researchers compared the immune response in CLL patients to that of healthy individuals.

Vaccination in CLL Patients: An Immune Desert

The study revealed that CLL patients, despite receiving the PCV13 vaccine, had a weaker immune response than their healthy counterparts. This finding highlights the importance of tailored vaccination strategies for CLL patients, as their immune system may not mount a robust defense against infections.

Protecting Against Infections in CLL Patients: A Vital Need

This study emphasizes the need for continued research into vaccination strategies for CLL patients. Understanding the complexities of the immune system in CLL is crucial for developing effective strategies to protect these vulnerable individuals from infections. It's like finding a wellspring of knowledge in the vast desert of medical challenges.

Dr.Camel's Conclusion

This study provides valuable insights into the immune response to vaccination in CLL patients. The findings underscore the unique challenges posed by this disease and the need for tailored strategies to protect patients from infections. It's a reminder that even in the face of adversity, we can still strive for a better future for those battling this complex disease.

Date :
  1. Date Completed 2015-11-30
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

25506837

DOI: Digital Object Identifier

PMC4266633

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.